risks of taking compounded semaglutide semaglutide: Is it safe? FDA alerts health care providers,

[PubMed ID: 25806118]

With retatrutide and Foundayo, the company is targeting not just weight management but also health issues that often occur alongside obesity, where there is still substantial unmet medical need

By Nancy Lapid June 8 (Reuters) - Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests

It adds empty calories that work against weight loss goals

A supervised team matters because these are powerful prescription tools, not over-the-counter products

Researchers reveal benefits, risks linked to popular weight-loss drugs GLP-1 receptor agonists transform diabetes care, offering benefits to heart and brain health but posing risks to kidneys and pancreas Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity